Global Antibody Drug Conjugates Market 2024-2028

Global Antibody Drug Conjugates Market 2024-2028

The antibody drug conjugates market is forecasted to grow by USD 9.95 bn during 2023-2028, accelerating at a CAGR of 15.06% during the forecast period. The report on the antibody drug conjugates market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of cancer and other diseases, technological advancements in ADC development, and increasing investments in pharmaceutical research and development.

Technavio's antibody drug conjugates market is segmented as below:

By Application

• Breast cancer
• Blood cancer
• Others

By Technology

• Cleavable linker
• Non-cleavable linker
• Linkerless

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing adoption and development of targeted therapies as one of the prime reasons driving the antibody drug conjugates market growth during the next few years. Also, advancements in technology and manufacturing processes and increasing demand for personalized medicine in cancer treatment will lead to sizable demand in the market.

The report on the antibody drug conjugates market covers the following areas:

• Antibody drug conjugates market sizing
• Antibody drug conjugates market forecast
• Antibody drug conjugates market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antibody drug conjugates market vendors that include AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA. Also, the antibody drug conjugates market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.